For the future of all cancer patients

The three main standard treatments for cancer are surgery, radiation therapy and chemotherapy.

And now, immunotherapy is attracting attention as a “fourth cancer treatment”.

We aim to provide more effective regenerative cell therapy for the future of each patient,

from research and development of cutting-edge medical care.

For the future of
all cancer patients

The three main standard treatments for cancer are surgery, radiation therapy and chemotherapy.

And now, immunotherapy is attracting attention as a “fourth cancer treatment”.

We aim to provide more effective regenerative cell therapy for the future of each patient,

from research and development of cutting-edge medical care.

Services

Bioaccell Inc. are involved in the cultivation and processing of therapeutic immune cells for cancer immunotherapy.

License for the manufacture of specified cell-processed products
(Kinki Regional Bureau of Health and Welfare, Japan)
Facility No. FA5190003

Learn More

Services

We at Bioaccell Inc. are involved in the cultivation and processing of therapeutic immune cells for cancer immunotherapy.

License for the manufacture of specified cell-processed products
(Kinki Regional Bureau of Health and Welfare, Japan)
Facility No. FA5190003

Cellular medicine based on highly safe culture technology

The CPF (Cell Processing Factory), where cells are cultured, operates under a 24-hour computer system with a cleanliness level of Class 10,000.
Furthermore, management is based on a double-check system, and safety is always a priority.

Learn more about immune cell therapy

Cellular medicine based on highly safe culture technology

The CPF (Cell Processing Factory), where cells are cultured, operates under a 24-hour computer system with a cleanliness level of Class 10,000.
Furthermore, management is based on a double-check system, and safety is always a priority.

Learn more about immune cell therapy

Announcement of the start of joint research with Erasmus University Medical Center Rotterdam

Towards the practical application of AKT-DC therapy, which greatly improves the survival rate of lung cancer patients

　Bioaccell Inc. has decided to provide its immune cell culture and activation technology for preclinical trials to be conducted from 2021 for the practical application of AKT-DC therapy in the EU.
　This joint research project was led by Prof. Dr. Joachim Aerts of Erasmus University Medical Center Rotterdam (EMC Rotterdam) in the Netherlands, and was made possible with financial support from the Anticancer Fund (ACF), which is based in Brussels, Belgium.
　The ACF is a fund that does not pursue profit, but provides funding for technologies and research that can truly contribute to cancer patients. This project was made possible by Dr. An Van Nuffel, one of the people in charge at the ACF, recognizing the high therapeutic efficacy shown in the paper.

Press Release

Announcement of the start of joint research with Erasmus University Medical Center Rotterdam

Towards the practical application of AKT-DC therapy, which greatly improves the survival rate of lung cancer patients

　Bioaccell Inc. has decided to provide its immune cell culture and activation technology for preclinical trials to be conducted from 2021 for the practical application of AKT-DC therapy in the EU.
　This joint research project was led by Prof. Dr. Joachim Aerts of Erasmus University Medical Center Rotterdam (EMC Rotterdam) in the Netherlands, and was made possible with financial support from the Anticancer Fund (ACF), which is based in Brussels, Belgium.
　The ACF is a fund that does not pursue profit, but provides funding for technologies and research that can truly contribute to cancer patients. This project was made possible by Dr. An Van Nuffel, one of the people in charge at the ACF, recognizing the high therapeutic efficacy shown in the paper.

Press Release

Greetings from the President

In the last 10 years, the awareness of immunotherapy for cancer, centered on activated autologous lymphocyte therapy, has increased dramatically, and it has come to play a role in cancer treatment.
The direction of cancer treatment is beginning to take the course I had predicted some time ago.
This means that coexistence with cancer, i.e. maintaining a long-term stable condition, and a high quality of life (QOL) are now being strongly demanded by patients and others involved in cancer treatment. Many patients are already aware that treatment that utilizes the patient’s own immune system is essential for this.

Read More

President and CEO of Bioaccell Inc.
Shigeru Hirabayashi

Book Introduction

Our CEO, Shigeru Hirabayashi, is a science writer who has written many books.
Through his books, he is disseminating correct knowledge about cancer treatment and immune cell therapy.

悪性新生物
がんを生き抜く
医者のいいなりにならない「がん患者学」
進行がんを眠らせる

Introduction to the President & CEO

President and CEO of Bioaccell Inc.
Shigeru Hirabayashi

Greetings from the President

In the last 10 years, the awareness of immunotherapy for cancer, centered on activated autologous lymphocyte therapy, has increased dramatically, and it has come to play a role in cancer treatment.
The direction of cancer treatment is beginning to take the course I had predicted some time ago.
This means that coexistence with cancer, i.e. maintaining a long-term stable condition, and a high quality of life (QOL) are now being strongly demanded by patients and others involved in cancer treatment. Many patients are already aware that treatment that utilizes the patient’s own immune system is essential for this.

Read More

Book Introduction

Our CEO, Shigeru Hirabayashi, is a science writer who has written many books.
Through his books, he is disseminating correct knowledge about cancer treatment and immune cell therapy.

悪性新生物
がんを生き抜く
医者のいいなりにならない「がん患者学」
進行がんを眠らせる

Cutting-edge medical care that is close to your heart

We value the opinions of our patients.

Shigeru Hirabayashi, our company’s representative director, has been the representative of a cancer patient group called “Gathering of Patients,Mominoki” for many years. Mominoki is the Japanese word for Fir tree. Our company was established based on the “voices of patients”. In other words, it is a company created by a patient group for patients.
We listen carefully to the voices of patients and face them head-on.
We have seen many patients who cannot continue treatment even if it is effective because the cost of treatment is high.
That is why we aim to spread the word about immuno-cell therapy by making it possible to receive treatment in a relatively affordable way.

The website of the “Gathering of Patients, Mominoki”

Cutting-edge medical care that is close to your heart

We value the opinions of our patients.

Shigeru Hirabayashi, our company’s representative director, has been the representative of a cancer patient group called “Gathering of Patients,Mominoki” for many years. Mominoki is the Japanese word for Fir tree. Our company was established based on the “voices of patients”. In other words, it is a company created by a patient group for patients.
We listen carefully to the voices of patients and face them head-on.
We have seen many patients who cannot continue treatment even if it is effective because the cost of treatment is high.
That is why we aim to spread the word about immuno-cell therapy by making it possible to receive treatment in a relatively affordable way.

The website of the “Gathering of Patients, Mominoki”

Introduction of affiliated medical institutions

We will introduce some of the clinics and medical institutions that use Bioaccell’s technology.

Introduction of affiliated medical institutions

We will introduce some of the clinics and medical institutions that use Bioaccell’s technology.

Nakamura Digestive Clinic

RIKEN Immune Regenertive Medicene

Sakurazaka Clinic

IGT Clinic

Nakamura Digestive Clinic

RIKEN Immune Regenertive Medicene

Sakurazaka Clinic

IGT Clinic

Bioaccell Inc.

Head Office

#301 Kyodaikatura Venture plaza,
1-36, Gryo Ohara, Nishikyo-ku,
Kyoto-shi, Kyoto 615-8245, Japan

Phone: +81 75 394 6410
Fax: +81 75 394 6411
Mail: info@bioaccell.com

Tokyo Office

BAC HOUSE 4-19-3,
Ebisu,Shibuya-ku,
Tokyo 150-0013, Japan

Phone: +81 3 5475 6430
Fax: +81 35421 3433
Mail: info@bioaccell.com

WEB SITE MENU

Home
Business
Immune Cell Therapy
Message
Company
Contact

Language Switcher

US　English

JP　日本語